ReviewThe Lancet. Infectious diseases2024
Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions.
Review in The Lancet. Infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Antimicrobial Resistance inMedicina (Kaunas, Lithuania) · 2026Pooled it
- Pharyngeal gonorrhea in Ugandan men with urogenital gonorrhea: differences in antimicrobial resistance and strain types between anatomical sites.The Journal of infectious diseases · 2026Article
- Rapid detection of ceftriaxone-resistantMicrobiology spectrum · 2026Article
- Oral Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: Nucleic Acid Amplification Testing Outcomes in a Randomized, Multicenter Phase 3 Trial (EAGLE-1).Open forum infectious diseases · 2026Article
- Targeting Membrane Transport and Energy Metabolism for the Identification of Repurposed Drug Candidates AgainstAntibiotics (Basel, Switzerland) · 2026Article
- Evidence-Based Assessment of the Role of Pharyngeal Gonorrhea and Commensal Neisseria Species in the Emergence of Antimicrobial Resistance in Neisseria Gonorrhoeae: Data Gaps and Future Research.The Journal of infectious diseases · 2026Review
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- Global, Regional, and National Impact of Pelvic Inflammatory Disease: Changing Landscape from 1990 to 2021.International journal of women's health · 2026Article
- Emerging epidemic of the Africa-type plasmid in penicillinase-producingEmerging microbes & infections · 2025Article
- High prevalence and emerging cephalosporin resistance of penicillinase-producing Neisseria gonorrhoeae in Meizhou, China (2022-2024).BMC infectious diseases · 2025Article
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- [A NovelSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Article
- The Characterization of a Gonococcal HicAB Toxin-Antitoxin System Capable of Causing Bacteriostatic Growth Arrest.Microorganisms · 2025Article
- Rationale and Ethical Assessment of an Oropharyngeal Gonorrhea Controlled Human Infection Model.The Journal of infectious diseases · 2025Article
- Clinical Studies Are Needed to Determine the Efficacy of Ceftriaxone and Other Interventions in Addressing Resistant Neisseria gonorrhoeae Infection.Sexually transmitted diseases · 2025Article
- An oropharyngeal gonorrhoea controlled human infection model: a provisional protocol using a novelWellcome open research · 2025Article
- NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae.NPJ vaccines · 2024Article
- How Do Gepotidacin and Zoliflodacin Stabilize DNA Cleavage Complexes with Bacterial Type IIA Topoisomerases? 1. Experimental Definition of Metal Binding Sites.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Due to the continued emergence of resistance to extended-spectrum cephalosporin antibiotics, clinicians are increasingly more likely to encounter cases of Neisseria gonorrhoeae treatment failure. The current international treatment guidelines offer few regimens for cases of N gonorrhoeae infection that do not respond to first-line therapy, and there are many complexities that should be considered with such regimens; these include regional variations in resistance to alternative agents, access to different antibiotics, and penetration of those antibiotics within different tissues. Further, such regimens do not account for the challenges of treating pharyngeal infections; many patients who have not responded to treatment with extended-spectrum cephalosporin antibiotics to date have had pharyngeal involvement. In addition, pharyngeal infections play a pivotal role in the emergence and spread of antimicrobial resistance in N gonorrhoeae and are more difficult to treat than urogenital infections because of the unfavourable pharmacokinetics of cephalosporins in pharyngeal tissues. Here, we summarise the current guidelines, provide additional approaches and considerations for clinicians, and highlight knowledge gaps that should be addressed to ensure appropriate therapy in cases of treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.